An Executive Informational Overview (EIO) is now available on Sunshine Biopharma Inc., a revenue-generating pharmaceutical company offering life-saving medicines within a variety of therapeutic areas, including oncology and antivirals. The 56-page report details the Company's business, its strategy, market opportunities, competition, financials, risks, and more. It is available for download below.
Snapshot
Sunshine Biopharma Inc. (“Sunshine Biopharma” or “the Company”) is a revenue-generating pharmaceutical company offering life-saving medicines within a variety of therapeutic areas, including oncology and antivirals. The Company’s proprietary therapeutic drug development program includes three product candidates: (1) Adva-27a, a small chemotherapy molecule for pancreatic cancer, (2) K1.1, a messenger RNA (mRNA) therapeutic for liver cancer, and (3) SBFM-PL4, a PLpro inhibitor for the treatment of COVID-19. Sunshine Biopharma’s proprietary pharmaceutical pipeline addresses large markets with significant unmet needs in oncology and anti-viral indications, creating a diversified portfolio with a combined market potential of over $30 billion for the initial targeted indications. In addition to its proprietary drug development efforts, the Company also operates two wholly-owned subsidiaries: Nora Pharma Inc., a Canadian corporation with a portfolio of over 50 generic prescription drugs; and Sunshine Biopharma Canada Inc., a Canadian corporation, which sells over-the-counter (OTC) supplements. According to the Company, the growth of its revenue-generating generic pharmaceutical business, through the operations of Nora Pharma, places Sunshine Biopharma on track to achieve profitability by FY 2025, with the generated cash flow expected to support and facilitate the development of its proprietary pharmaceutical pipeline. Sunshine Biopharma’s revenue generating generic pharmaceutical business, in conjunction with its focused proprietary drug development efforts, provides a low-risk model where the lengthy pharmaceutical development and approval process is supported by revenue generating activities.
Key Points of Sunshine Biopharma Inc..
- On October 20, 2022, Sunshine Biopharma acquired Nora Pharma Inc., a generic pharmaceutical company that currently offers 50 generic prescription drugs in Canada with another 27 drugs scheduled to be launched in 2023 and 2024.
- In preclinical trials, both Adva-27a and K1.1 have been effective against multidrug resistant (MDR) cancer cells in vitro, including pancreatic and breast cancer cells, among others.
- In February 2023, the Company signed a research agreement with the Jewish General Hospital in Montreal, Canada, to advance the development of Adva-27a through IND-enabling studies as well as negotiated terms for a subsequent Phase I clinical trial in patients with Stage 4 pancreatic cancer.
- The Company is conducting a proof-of-concept mice study to assess K1.1 in vivo effect on liver cancer, with results expected by October/November 2023. Follow up toxicology studies are scheduled for 2Q 2024.
- The Company plans to conduct explorative toxicity studies for SBFM-PL4 (expected 4Q 2023 to 2Q 2024).
- As of June 30, 2023, Sunshine Biopharma had a cash and cash equivalent position of $19.7 million.
*******************************************
Visit our Corporate Profile and Investment Highlights pages
for the latest research on Sunshine Biopharma Inc.
*******************************************